Document:

Exhibit 10.1

 

 

 

Sol J. Barer

2 Barer Lane

Mendham, NJ 07945

 

August 6, 2012

 

RE: Medgenics, Inc. (the “Company”)

 

Dear Sol,

 

I am writing to you on behalf of the board of directors of the
Company to confirm arrangements with regard to the terms of appointment to office as a director of the Company from the date of
Your Appointment (June 30, 2012) and further appointment as Chairman of the Board.

 

		1	Definitions

For the purposes of this Letter, the following words or expressions
shall have the following meanings respectively:

 

	“AIM”	means the AIM Market of London Stock Exchange plc;
	 	 
	“Biopump”	means a micro organ which has undergone ex-vivo transduction with a vector such that it produces and secretes a desired therapeutic protein;
	 	 
	“Board”	means the board of directors of the Company, including any committee of the Board duly constituted by it;
	 	 
	"Businesses"	means:

 

		(a)	the business of the research, development, design, production, manufacturing, marketing, sale, distribution and other commercial
activities of any Group Company in relation to the Group’s proprietary and/or licensed technology concerning a platform
technology for the treatment of various diseases and/or chronic disorders and conditions whereby
a sliver of human dermal tissue is converted into an internal protein production plant, through ex vivo transduction with
a viral or non-viral vector, and the processed tissue is re-implanted under the human donor’s skin to provide therapeutic
levels of protein delivery; and

 

		(b)	any other business that any Group Company shall at the relevant date;

 

		(i)	be engaged in and with which you shall have been concerned or involved to any material extent at any time during Your Appointment;
or

 

		(ii)	have determined to carry on with a view to developing any other biotechnical technology for commercial exploitation in the
future and in relation to which determination you shall at the Termination Date possess any material Confidential Business Information;

 

	"Confidential Business 

Information"	means all and any Corporate Information, Marketing Information, Technical Information and other information (whether or not recorded in documentary form or on computer disk or tape) which the Company or any Group Company treats as confidential or in respect of which it owes an obligation of confidentiality to any third party, which is not in the public domain:
		

 

    	 

    	 

    
 

 

		(a)	which you shall have acquired or shall hereafter acquire at any time during Your Appointment but which does not form part of
your own stock in trade; and

 

		(b)	which is not readily ascertainable to persons not connected with the Company or any Group Company;

 

	“Corporate Information"	means all and any information (whether or not recorded in documentary form or on computer disk or tape) relating to the business methods, corporate plans, management systems, finances, maturing new business opportunities or research and development projects of the Company or any Group Company;
	 	 
	“DGCL”	means Delaware General Corporation Law;
	 	 
	“Group”	means the Company and its affiliates, including any company that controls, is controlled by, or is under common control with the Company, as defined in Rule 3b-18 of the Securities Exchange Act of 1934, as amended from time to time, including, without limitation to the generality of the foregoing, Medgenics Medical (Israel) Limited;
	 	 
	“Group Company”	means a member of the Group and “Group Companies” shall be interpreted accordingly;
	 	 
	"Marketing Information"	means all and any information (whether or not recorded in documentary form or on computer disk or tape) relating to the marketing or sales of any past present or future product or service of the Company or any Group Company including, without limitation, sales targets and statistics, market share and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount structures, advertising and promotional material, the names, addresses, telephone numbers, contact names and identities of customers and potential customers of and suppliers and potential suppliers to the Company or any Group Company, the nature of their business operations, their requirements for any product or service sold to or purchased by the Company or any Group Company and all confidential aspects of their business relationship with the Company or any Group Company;
	 	 
	"Material Interest"	means:

 

		(a)	the holding of any position as director, officer, employee, consultant, partner, principal or agent;

 

		(b)	the direct or indirect control or ownership (whether jointly or alone) of any shares (or any voting rights attached to them)
or debentures save for the ownership for investment purposes only of not more than five percent (5%) of the issued shares of any
company whose shares are listed on any national securities exchange (as defined in Section 3(a)(1) of the Securities Exchange Act
of 1934, as amended from time to time), or any similar exchange in jurisdictions outside the United States, including AIM; or

 

		(c)	the direct or indirect provision of any finance;

 

other than on behalf of any Group Company for the
legitimate purposes of that Group Company;

 

	"Technical Information"	means all and any trade secrets, secret formulae, processes, inventions, designs, know-how discoveries, technical specifications and other technical information (whether or not recorded in documentary form or on computer disk or tape) relating to the creation, production or supply of any past, present or future product or service of the Company or any Group Company;

 

    	 

    	 

    
 

 

	 	 
	“Termination Date”	means the date of the termination of Your Appointment; and
	 	 
	“Your Appointment”	means your appointment to and holding of office as a director of the Company as confirmed by this letter.

 

		2	Duties

 

		2.1	As a director of the Company you will be expected to exercise the general fiduciary duties and duties of care and loyalty as
provided under the DGCL and provide such advice and services as the Board may reasonably require.

 

		2.2	The Board as a whole is collectively responsible for the success of the Company. The Board's role is to:

 

		2.2.1	provide entrepreneurial leadership of the Company within a framework of prudent and effective controls, which enable risk to
be assessed and managed;

 

		2.2.2	set the Group’s strategic aims, ensure that the necessary financial and human resources are in place for the Company
to meet its objectives and review management performance; and

 

		2.2.3	set the Company’s values and standards and ensure that its obligations to its shareholders and others are understood
and met.

 

		2.3	In your role as a non-executive director, you shall be
required to:

 

		2.3.1	constructively challenge and contribute to the development of the Group’s strategy;

 

		2.3.2	scrutinise the performance of management in meeting agreed goals and objectives and monitor the reporting of performance;

 

		2.3.3	satisfy yourself that financial information is accurate and that financial controls and systems of risk management are appropriate,
robust and defensible;

 

		2.3.4	endeavour to attend all meetings of the Board and the annual and all other meetings of the shareholders of the Company;

 

		2.3.5	at all times comply with the certificate of incorporation and bylaws of the Company, each as the same may be amended or restated
from time to time;

 

		2.3.6	abide by your fiduciary duties as a director of the Company;

 

		2.3.7	diligently perform your duties;

 

		2.3.8	immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any other employee or director of the Company
of which you become aware to the Chairman of the Company; and

 

		2.3.9	comply with the terms of the Code of Business Conduct and Ethics adopted by the Board ( a copy of which is annexed hereto)
and any other code of practice issued by the Company from time to time relating to dealing in the Company's securities.

 

		2.4	In addition, your duties shall require that you shall:

 

		2.4.1	promote the highest standards of integrity, probity and corporate governance throughout the Company, particularly at Board
level;

 

		2.4.2	use your best endeavours to ensure that the Board receives accurate, timely and clear information;

 

		2.4.3	use your best endeavours to ensure effective communication with shareholders;

 

		2.4.4	use your best endeavours to facilitate the effective contribution of non-executive directors and to ensure constructive relations
are maintained between the executive and non-executive directors;

 

		2.4.5	ensure that the performance of the Chief Executive Officer (and of any other executive director(s) from time to time) is evaluated
at least once a year; and

 

    	 

    	 

    
 

 

		2.4.6	at the request of the Company, serve on committees of the Board as shall be agreed between you and the Chairman of the Company.

 

		3	Time Commitment

 

You shall work such hours per week over the term Your Appointment
as are necessary for the proper performance of your duties as a non-executive director of the Company.

 

		4	FEES 

 

You will be entitled to certain cash fees in connection with
your services as set forth below:

 

	i.	Annual retainer fee	$ 12,000
	ii.	Per Meeting fee (including telephonic)	$   1,500
	iii.	Per Meeting fee (outside U.S.)	$   2,500
	iv.	Per Committee Meeting (if not associated with an on-site Board Meeting)	$  1,000
	v.	Annual retainer fee for director acting as Chairman of committee (per committee)	$  2,500

 

 

A year for this purpose shall be a period commencing on the
date of Your Appointment or on any first anniversary hereof and ending 12 consecutive calendar months thereafter. This fee and
the terms prescribing the frequency of payment shall be fixed for a period of one (1) year from the date of Your Appointment and
thereafter shall be subject to review. On termination of Your Appointment you will (if applicable) be paid your director’s
fee on a pro-rata basis, to the extent unpaid up to the Termination Date.

 

You will receive stock options to acquire 900,000 shares of
common stock upon Your Appointment, subject to the approval by NYSE MKT of an additional listing application covering such shares
(the date of such approval shall be referred to as the “Approval Date”). Such options will be issued outside the Company’s
2006 Stock Incentive Plan, as amended (the “Stock Plan”), and will vest in three equal installments, with the first
300,000 options vesting on the Approval Date, the second 300,000 options vesting on June 30, 2013 and the remaining options vesting
on June 30, 2014. You will be entitled to participate in any equity compensation program established for non-executive directors
beginning in 2013. Currently, the Company has established a plan to make annual restricted share and option grants under the Stock
Plan to be made on January 2nd of each year (or on the first business day hereafter or (as applicable) as soon as practical
thereafter when the Company is not in a close period) as follows (i) 7,000 shares of restricted stock with 50% vesting one day
after grant and the remaining 50% vesting on the first anniversary of grant; and (ii) options to purchase 15,000 shares, having
a 10 year term and vesting in equal installments over 3 years. You acknowledge that the Company may determine to change this equity
compensation program and this Letter shall in no way be deemed to be a guarantee of future option grants.

 

		5	Term of office

 

Your Appointment commenced on June 30, 2012 and shall continue
following such date unless or until your successor is elected and qualified or until your earlier resignation or removal. You agree
that you will give not less than sixty (60) days’ (or such lesser period if agreed by the Board) prior notice in writing
to the Company in the event you wish to resign prior to the expiration of your term or in the event you do not wish to stand for
re-election at the Company’s annual meeting of stockholders.

 

For the avoidance of doubt, by your
counter-signature hereto, you acknowledge that your continuation in office is subject to the DGCL and the certificate of
incorporation and bylaws of the Company, each as the same may be amended or restated from time to time.

    	 

    	 

    
 

 

On termination of Your Appointment for whatever reason you will
promptly return to the Company all documents, records, keys, correspondence or other items in your possession or under your control
which relate in any way to the business or affairs of, or are the property of, the Company or any Group Company and all copies
thereof, regardless of the medium upon or in which such copies are stored or held. In addition, you will cease to use the Company’s
facilities and cease to hold yourself out as being a director of the Company.

 

		6	Expenses

 

The Company shall reimburse you in respect of all reasonable
travelling, hotel, entertainment and other out of pocket expenses properly and necessarily incurred by you in or about the performance
of your duties under this Agreement, subject to the production (if requested) of any receipts, vouchers and other supporting documentation
that the Company shall reasonably require.

 

		7	Confidentiality

 

		7.1	Both during the currency and after the Termination Date, you will treat all Confidential Business Information as confidential
and not use or disclose the same to any other party except:

 

		7.1.1	insofar as may be necessary for the proper and effective performance of your duties as a director of the Company and then only
to a person who shall be subject to equivalent, express, written confidentiality obligations to the Company or a Group Company;

 

		7.1.2	to the extent that such information is or (without default of your part) becomes generally available to the public; or

 

		7.1.3	to the extent that you shall be required to disclose the same by any applicable law or legally binding order of any court,
government, semi-governmental authority, administrative or judicial body, or a legally binding requirement of a stock exchange
or regulator.

 

		7.2	If you are required to make a disclosure as contemplated in clause 7.1.3:

 

		7.2.1	you must disclose only the minimum Confidential Business Information required to comply with the applicable law, order
or requirement; and

 

		7.2.2	before making such disclosure, you must:

 

		(a)	give the Company reasonable written notice of:

 

		(i)	the full circumstances of the requirement for disclosure arising; and

 

		(ii)	the Confidential Business Information which you propose to disclose; and

 

		(b)	consult with the Company as to the form of the disclosure.

 

		7.3	By your counter-signature hereto, you acknowledge that:

 

		7.3.1	the Company and each Group Company possess a valuable body of Confidential Business Information;

 

		7.3.2	the Company has given and will continue to give you access to Confidential Business Information in order that you may carry
out your duties hereunder;

 

		7.3.3	your duties include, without limitation, a duty of care and a duty of loyalty as provided under the DGCL; and

 

		7.3.4	the disclosure of any Confidential Business Information other than for the legitimate business purposes of the Company or any
Group Company, including (without limitation) to an actual or potential competitor of the Company or any Group Company could place
such company at a serious competitive disadvantage and could cause immeasurable (financial and other) damage to the Businesses

 

			and that the obligations of confidentiality assumed under the provisions of this clause 7 are reasonable and necessary for
the protection of the Group, the Businesses and the Confidential Business Information.

 

    	 

    	 

    
 

 

		8	Other Interests and Restrictions

 

		8.1	It is accepted and acknowledged that you have business interests other than those of the Company and that you have declared
any potential conflicts that are apparent at present. If you become aware of any potential conflicts of interest after the date
of Your Appointment, these should be disclosed to the Chairman of the Company and company secretary as soon as you become aware
thereof.

 

		8.2	By your counter-signature hereto, you agree and undertake that, during the term of Your Appointment,
you shall not, without the Company's written permission, assume or hold any Material Interest in any person, firm or company which:

 

		8.2.1	impairs or might reasonably be thought by the Board to impair your ability to act at all times in the best interests of the
Company; or

 

		8.2.2	requires or might reasonably be thought by the Board to require you to disclose any Confidential Business Information in order
properly to discharge your duties to or to further your interest in such person, firm or company.

 

		8.3	By your counter-signature hereto, you agree and undertake that you will not, without the Company’s written permission,
during the term of Your Appointment and for the period of 12 months after the Termination Date, in any part of the world, whether
directly or indirectly:

 

		8.3.1	assume or hold a Material Interest in a business which manufactures, distributes or utilizes the Group’s Biopump technology
using Biopumps;

 

		8.3.2	solicit, or by any other means induce or seek to induce, any person, firm or company with whom or which any Group Company transacts
business (whether as customer, supplier, contractor, licensor, adviser or otherwise in relation to the Business) to cease dealing
with such Group Company or to restrict or vary the terms upon which it deals with such Group Company;

 

		8.3.3	solicit or entice away or employ or engage or seek to entice away from any Group Company any person who is and was at the Termination
Date or at any time during the six (6) months prior to the Termination Date a director, scientific adviser, regulatory adviser,
bioscience engineer or other scientific, program, product development, marketing, sales, licensing, research and development and/or
other senior manager, key salesperson or secretary (if any) assigned to you; and

 

		8.3.4	enter into a license with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”)
for any of the technologies that are currently expressly excluded from the “Scope” of the Agreement between Yissum
and the Company dated November 23, 2005 (the “Yissum License”), as set forth on Appendix A of the Yissum License.

 

		8.4	By your counter-signature hereto, you agree and undertake that you will not at any time after the Termination Date, represent
or hold yourself out or permit yourself to be represented or held out by any person, firm or company as being in any way then currently
connected with or interested in the Company or any Group Company other than (if such be the case) as the holder of shares, options
and/or warrants in the Company.

 

		8.5	Each of the provisions of clauses 8.2, 8.3 and 8.4 and (where applicable) the sub-clauses thereof is independent and severable
from the remaining provisions and enforceable accordingly. If any provision of the said clauses/sub-clauses shall be unenforceable
for any reason but would be enforceable if part of the wording thereof were deleted, it shall apply with such deletions as may
be necessary to make it enforceable.

 

		8.6	You have given the undertakings contained in this clause 8 to the Company itself and to the Company as trustee for the benefit
of each Group Company and will, at the request and cost of the Company, promptly enter into direct undertakings with any Group
Company which correspond to the undertakings in this clause 8.

 

    	 

    	 

    
 

 

		8.7	The Company agrees that each Material Interest that you assume or hold as of the date hereof is hereby permitted.

 

		9	Independent Legal Advice

 

Occasions may arise when you consider that
you will need professional advice in connection with the performance of your duties as a director of the Company and you will be
able to consult the Company’s advisors for this purpose. Exceptional circumstances may occur when it may be appropriate for
you to seek such advice from independent advisors, at the Company’s expense. In such an event, you should, where reasonably
practical and not (in your reasonable judgment) prejudicial to the interests of the Company, consult with the Board or, if you
consider appropriate, the non-executive directors, prior to such advice being sought or expense being incurred.

 

		10	Governing law and jurisdiction

 

This Letter shall be governed by and shall be interpreted in
accordance with the DGCL. The parties irrevocably submit to the non-exclusive jurisdiction of the state courts of Delaware, USA
in relation to all matters arising out of or in connection with this appointment letter.

 

On a more personal note, I want to tell you how pleased I am
that you are joining the Medgenics Board of Directors and assuming the role of Chairman of the Board. I know that I speak for the
other directors in saying that we look forward to your leadership and contributions as a director. As required by AIM rules, I
should be grateful if you would please confirm your acceptance of the terms of your appointment by signing and returning the duplicate
of this Letter.

 

With kind regards,

 

 

 

/s/ Eugene A. Bauer

 

Eugene A. Bauer, M.D.

 

Duly authorised for and on behalf of the Board

 

 

 

 

 

I hereby acknowledge the above terms and agree and undertake
in the above terms.

 

 

	SIGNED AS A DEED	)	 
	 	 	 
	by Sol J. Barer	)	 
	 	 	 
	in the presence of:-	)	/s/ Sol J. Barer
	 	 	 
	 	 	Sol J. Barer

 

	Witness Signature:	/s/ Meri Barer
	 	 
	Name:	Meri Barer
	 	 
	Address:	2 Barer Lane
	 	 
	 	Mendham, NJ 07945
	 	 
	Occupation:	RetiredAMENDMENT NO. 1 

TO EXCHANGE TRANSACTION AGREEMENT

 

This Amendment No. 1 (this “Amendment”) to that
certain Exchange Transaction Agreement (the “Agreement”), dated as of December 29, 2011, by and among Opus Point Partners,
LLC, a Delaware corporation (“Opus”), TG Biologics, Inc. (f/k/a TG Therapeutics, Inc.), a Delaware corporation (“TG
Biologics”) and TG Therapeutics, Inc. (f/k/a Manhattan Pharmaceuticals, Inc.), a Delaware corporation (“TG Therapeutics”),
is entered into by and among the aforementioned parties (Opus, TG Biologics and TG Therapeutics, collectively, the “Parties”),
this 2nd day of August 2012. TG Therapeutics agrees to be bound by the terms and conditions of the Agreement, as amended
herein. All capitalized terms not herein defined shall have the meaning ascribed to them in the Agreement and that certain Confidential
Offering Memorandum, dated December 1, 2011, as amended or supplemented from time to time, including all attachments, schedules
and exhibits thereto.

 

The Parties hereby agree to the following amendments:

 

		1.	Section 5.5(a) of the Agreement is hereby stricken in its entirety and replaced with the following:

 

The Board of Directors of the Company shall be set
at six members, and shall not be increased without the consent of Opus. In addition, at every annual meeting of the stockholders,
or at any special meeting to elect directors, Opus shall have the right to nominate three of the six members of the Board of Directors
of the Company, until the later of (x) two years from the Closing Date, or (y) the date on which Opus is less than a beneficial
owner of 10% of the Company as calculated pursuant to the rules and regulations under Section 13 of the Securities Exchange Act
of 1934, as amended.

 

		2.	All references to “Opus” in the Agreement shall mean Opus and affiliates.

 

		3.	Section 1.1 of the Agreement is revised to add the following definition:

 

“Affiliate” shall mean any director, member
or officer of Opus and any person who is under the control of, or common control with Opus.

 

Each of the Parties shall execute such further documents and
instruments and take such further actions as may reasonably be requested by any other Party in order to effect the amendments contemplated
herein.

 

Except as set forth herein, the Agreement shall remain in full
force and effect.

 

[Signature Page Follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Parties have duly executed this Amendment,
which may be executed in one or more counterparts, all of which together constituting one and the same agreement, as of the date
first set forth above.

 

TG THERAPEUTICS, INC.

 

 

	By:	/s/ Michael Weiss	 	 
	 	Name: Michael Weiss
	 	Title:   Chief Executive Officer
	 	 
	 	 
	TG BIOLOGICS, INC.
	 
	 
	By:	/s/ Michael Weiss	 	 
	 	Name: Michael Weiss
	 	Title:   Chief Executive Officer
	 	 
	 	 
	OPUS POINT PARTNERS, LLC
	 
	 
	By:	/s/ Michael Weiss	 	 
	 	Name: Michael Weiss
	 	Title: Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]